Eugene Schneider - 29 Jan 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Reporting relationship: EVP, Chf Clinical Develop Ofcr
Issuer ticker: IONS
Reported as of: 29 Jan 2026
Net transaction value: -$515,630
SEC form: 4
Accepted by SEC: 02 Feb 2026, 20:52:06 UTC
Prior SEC filing: 20 Jan 2026
Next SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider

Key filing fact

Eugene Schneider filed Form 4 for IONIS PHARMACEUTICALS INC (IONS) on 02 Feb 2026.

Key facts

This page summarizes Eugene Schneider's Form 4 filing for IONIS PHARMACEUTICALS INC (IONS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 02 Feb 2026, 20:52.

Change

Previous filing in this sequence was filed on 20 Jan 2026.
Current net transaction value: -$515,630.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001838539 Primary reporting owner

Schneider Eugene

Relationship: EVP, Chf Clinical Develop Ofcr
Address: 2855 GAZELLE COURT, CARLSBAD
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider
Signature date: 02 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IONS transaction

Common Stock

Award

Transaction value: $0
Shares: +11,991
Change %: +19%
Price: $0.000000
Shares after: 75,881
Date: 29 Jan 2026
Ownership: Direct
Footnotes: F1

IONS transaction

Common Stock

Sale

Transaction value: $515,630
Shares: -6,179
Change %: -8.1%
Price: $83.45
Shares after: 69,702
Date: 30 Jan 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.32 to $83.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.